TEL AVIV, Israel and NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) — Shield, the world’s leading communication compliance platform, today launched new hybrid cloud infrastructure technology that provides financial institutions with flexible, scalable data solutions that make digital communication compliance efficient and adaptable within their existing data strategy. Read...
Read MoreDUBAI, United Arab Emirates & NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–NOW Money, the GCC’s first mobile banking solution focused on financial inclusion, and ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced a collaboration to implement ThetaRay’s cloud-based AML solution to monitor cross-border payments and support in the prevention of financial crimes and money laundering on the fintech’s payments platform. Read more...
Read MoreToday’s drug screening methods use one or two types of data. However, disease biology is not replicable by simple screening models because diseases are complex and heterogenous. However, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the entire history of medicine. In this article, Dr Aaron Daugherty, Vice President of Discovery at Aria Pharmaceuticals, shares evidence of how we might be missing potential breakthrough therapies. Read...
Read MoreGuest commentary written by Eyal Harel, CEO of BlueGreen Water Technologies California’s new climate strategy for slashing greenhouse gas emissions and meeting ambitious carbon neutrality goals is bold and transformative at best and an aspirational pipedream at worst. Read more...
Read MoreInterview with Ofer Sharon. Ofer Sharon is the CEO of OncoHost, a biotech company in the precision oncology space. A physician by training, Sharon has leveraged his experience in pharma drug development and entrepreneurship to lead OncoHost through the development of PROphet, the company’s host response profiling platform, which will launch in the U.S. for non-small cell lung cancer (NSCLC) patients in February 2023. Read...
Read More
